These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28671058)

  • 21. Prolyl Isomerase Pin1 in Human Cancer: Function, Mechanism, and Significance.
    Pu W; Zheng Y; Peng Y
    Front Cell Dev Biol; 2020; 8():168. PubMed ID: 32296699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Mechanism of the Pin1-Histone H1 Interaction.
    Jinasena D; Simmons R; Gyamfi H; Fitzkee NC
    Biochemistry; 2019 Feb; 58(6):788-798. PubMed ID: 30507159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of the Minichromosome Maintenance Protein 3 (MCM3) Chromatin Binding by the Prolyl Isomerase Pin1.
    Schumann M; Malešević M; Hinze E; Mathea S; Meleshin M; Schutkowski M; Haehnel W; Schiene-Fischer C
    J Mol Biol; 2018 Dec; 430(24):5169-5181. PubMed ID: 30316783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The peptidyl-prolyl isomerase PIN1 relieves cyclin-dependent kinase 2 (CDK2) inhibition by the CDK inhibitor p27.
    Cheng CW; Leong KW; Ng YM; Kwong YL; Tse E
    J Biol Chem; 2017 Dec; 292(52):21431-21441. PubMed ID: 29118189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural and kinetic analysis of prolyl-isomerization/phosphorylation cross-talk in the CTD code.
    Zhang M; Wang XJ; Chen X; Bowman ME; Luo Y; Noel JP; Ellington AD; Etzkorn FA; Zhang Y
    ACS Chem Biol; 2012 Aug; 7(8):1462-70. PubMed ID: 22670809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the role of PIN1 in hepatocellular carcinoma.
    Cheng CW; Leong KW; Tse E
    World J Gastroenterol; 2016 Dec; 22(45):9921-9932. PubMed ID: 28018099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thermodynamics of phosphopeptide binding to the human peptidyl prolyl cis/trans isomerase Pin1.
    Daum S; Fanghänel J; Wildemann D; Schiene-Fischer C
    Biochemistry; 2006 Oct; 45(39):12125-35. PubMed ID: 17002312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanistic insights into Pin1 peptidyl-prolyl cis-trans isomerization from umbrella sampling simulations.
    Di Martino GP; Masetti M; Cavalli A; Recanatini M
    Proteins; 2014 Nov; 82(11):2943-56. PubMed ID: 25066180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neighboring phosphoSer-Pro motifs in the undefined domain of IRAK1 impart bivalent advantage for Pin1 binding.
    Rogals MJ; Greenwood AI; Kwon J; Lu KP; Nicholson LK
    FEBS J; 2016 Dec; 283(24):4528-4548. PubMed ID: 27790836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Peptidyl-prolyl Cis-trans Isomerase NIMA-interacting 1: A Structure-based Virtual Screening Approach to Find Novel Inhibitors.
    da Costa KS; Galúcio JM; de Jesus DA; Gomes GC; Lima E Lima AH; Taube PS; Dos Santos AM; Lameira J
    Curr Comput Aided Drug Des; 2020; 16(5):605-617. PubMed ID: 31654518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pin1: a multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers].
    Marsolier J; Weitzman JB
    Med Sci (Paris); 2014; 30(8-9):772-8. PubMed ID: 25174754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy.
    Chen Y; Wu YR; Yang HY; Li XZ; Jie MM; Hu CJ; Wu YY; Yang SM; Yang YB
    Cell Death Dis; 2018 Aug; 9(9):883. PubMed ID: 30158600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptidyl-Prolyl cis/trans Isomerase NIMA-Interacting 1 as a Therapeutic Target in Hepatocellular Carcinoma.
    Kim G; Kim JY; Choi HS
    Biol Pharm Bull; 2015; 38(7):975-9. PubMed ID: 26133706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 associates with insulin receptor substrate-1 and enhances insulin actions and adipogenesis.
    Nakatsu Y; Sakoda H; Kushiyama A; Zhang J; Ono H; Fujishiro M; Kikuchi T; Fukushima T; Yoneda M; Ohno H; Horike N; Kanna M; Tsuchiya Y; Kamata H; Nishimura F; Isobe T; Ogihara T; Katagiri H; Oka Y; Takahashi S; Kurihara H; Uchida T; Asano T
    J Biol Chem; 2011 Jun; 286(23):20812-22. PubMed ID: 21454638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorylation-Dependent Pin1 Isomerization of ATR: Its Role in Regulating ATR's Anti-apoptotic Function at Mitochondria, and the Implications in Cancer.
    Makinwa Y; Musich PR; Zou Y
    Front Cell Dev Biol; 2020; 8():281. PubMed ID: 32426354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases.
    Legname G; Virgilio T; Bistaffa E; De Luca CMG; Catania M; Zago P; Isopi E; Campagnani I; Tagliavini F; Giaccone G; Moda F
    Prion; 2018 Mar; 12(2):127-137. PubMed ID: 29676205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalent overexpression of prolyl isomerase Pin1 in human cancers.
    Bao L; Kimzey A; Sauter G; Sowadski JM; Lu KP; Wang DG
    Am J Pathol; 2004 May; 164(5):1727-37. PubMed ID: 15111319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIN1 in Cell Cycle Control and Cancer.
    Cheng CW; Tse E
    Front Pharmacol; 2018; 9():1367. PubMed ID: 30534074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of the prolyl isomerase PIN1 promotes cell growth in osteosarcoma cells.
    Zhou L; Park BH; Park JH; Jang KY; Park HS; Wagle S; Lee KB; Kim JR
    Oncol Rep; 2013 Jan; 29(1):193-8. PubMed ID: 23129219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 4,6-bis(benzyloxy)-3-phenylbenzofuran as a novel Pin1 inhibitor to suppress hepatocellular carcinoma via upregulating microRNA biogenesis.
    Fan X; He H; Li J; Luo G; Zheng Y; Zhou JK; He J; Pu W; Zhao Y
    Bioorg Med Chem; 2019 Jun; 27(11):2235-2244. PubMed ID: 31027708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.